A 21st century cure for medtech innovationA 21st century cure for medtech innovation

FDA just can't catch a break. Often criticized by medical device manufacturers for overly burdensome regulations that delay innovative medical technologies from coming to market in a timely manner, it is also routinely taken to task by other stakeholders for being too lax in its regulatory oversight. Two cardiologists have expressed the latter view in a strident op-ed piece in the New York Times, which calls on the Senate to oppose the 21st Century Cures Act. The bill passed the House with rare across-the-aisle support in a 344-77 vote on July 10 and is now with the Senate.